Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.56 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295339 | 0.83 | BCHE (0.64) | RAB9AALDH1A1NR4A1NR4A2NR4A3 | |
| SCHEMBL2299514 | 0.82 | MAOB (0.61) | RAB9ANPC1ALDH1A1NR4A1NR4A2 | |
| SCHEMBL4413289 | 0.81 | KDM4E (0.60) | RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL2295843 | 0.81 | BCHE (0.61) | NR4A1NR4A2NR4A3EGFRMAOB | |
| SCHEMBL2294574 | 0.79 | MAOB (0.65) | RAB9ANPC1ALDH1A1NR4A1NR4A2 | |
| SCHEMBL29953819 | 0.77 | NR4A1 (0.66) | RAB9AALDH1A1NR4A1NR4A2NR4A3 | |
| SCHEMBL9718167 | 0.77 | NR4A1 (0.70) | RAB9ANPC1ALDH1A1NR4A1NR4A2 | |
| SCHEMBL2294560 | 0.77 | ENPP3 (0.50) | ALDH1A1KDM4EEGFRSMN1; SMN2MAPT | |
| SCHEMBL2294714 | 0.77 | BCHE (0.63) | RAB9ANPC1ALDH1A1NR4A1NR4A2 | |
| SCHEMBL27396445 | 0.77 | MAOB (0.66) | RAB9ANPC1ALDH1A1NR4A1NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | RAB9A 3397/4885NPC1 1685/4885ALDH1A1 1251/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | RAB9A 3397/4885NPC1 1685/4885ALDH1A1 1251/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | RAB9A 3397/4885NPC1 1685/4885ALDH1A1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.